spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

BioGenes Establishes Scientific Advisory Board

BioGenes GmbH


Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:

  • Prof. Dr. Hans Henning von Horsten, Industrial Biomanufacturing, HTW-Berlin University of
  • Applied Sciences, Berlin
  • Prof. Dr. Frank F. Bier, Dept. Biosystems Integration and Process Automatisation, Fraunhofer
  • IZI-BB, Potsdam-Golm
  • Dr. Wieland Wolf, CEO ProBioGen AG, Berlin
  • Dr. Jens Knauer, Method Development Virology Testing Quality Control, IDT Biologika GmbH, Dessau-Rosslau
The Scientific Advisory Board will provide BioGenes with significant expertise and experience throughout the whole drug development and manufacturing value chain to help strengthen and extend the Company’s position in the field of quality control for biopharmaceuticals.

Dr. Alexander Knoll, Managing Director of BioGenes states: “We are pleased to welcome these renowned experts to BioGenes’ Scientific Advisory Board. Creating the SAB represents another important step forward for the Company. Its members bring a wealth of experience in the area of biomanufacturing and analytics and will provide crucial advice based on their specializations which will be essential to guide us in prioritizing and driving forward our goals.”

Prof. Dr. Hans Henning von Horsten is co-inventor of several patents and pending patent applications for the biomanufacturing business. He was among the key inventors of ProBioGen’s GlymaxX antibody engineering technology that was outlicensed to Boehringer-Ingelheim, Novartis, Thermo-Fisher Scientific and several other drug developers. Hans Henning von Horsten is also Head of the Working Group Biotechnology at the Berlin-Brandenburg branch of the VDI Association of German Engineers.

Prof. Dr. Frank F. Bier is the founder of the Molecular Bioanalytics branch of the Fraunhofer Institute
for Biomedical Engineering (Fraunhofer IBMT). In 2003, he was appointed Chair of Applied
Bioelectronics and Biochip Technology at the University of Potsdam. Since 2014 he is the Head of the
Department Biosystems Integration and Process Automatisation of the newly formed branch
Fraunhofer Institute for Cell Therapy and Immunology, Biotechnology and Bioproduction (Fraunhofer
IZI-BB) in Potsdam-Golm, Germany.

Dr. Wieland Wolf is the CEO of ProBioGen, an internationally operating Contract Development and Manufacturing Organization (CDMO). He has three decades of experience in the biopharmaceutical industry. Wieland Wolf was involved in pioneering product registrations at Bioferon GmbH, headed a production unit for API and parenteral dosage forms at the same company, and was responsible for the biotechnology division of the Rentschler Group, which he led through its transformation from a product-oriented enterprise into an established service provider and contract manufacturing organization (CMO). Wieland Wolf is the President of the European Association for Pharma Biotechnology and a member of the Board of Trustees of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (Fraunhofer IGB) in Stuttgart, Germany.

Dr. Jens Knauer has a strong background in GLP/GMP contract research, method development and as a Principal Investigator in several clinical trials. Before joining IDT Biologika GmbH, he was involved in the development and validation of immunological assays at the Fraunhofer Institute for Cell Therapy and Immunology where he was also instrumental in building a GLP laboratory for immunotoxicological assays.

About BioGenes
BioGenes GmbH specializes in highly sophisticated and customized antibody and immunoassay
development and is an experienced and reliable partner for process development improvements in all
areas of quality control, diagnostics and drug discovery. BioGenes is certified to meet the international
requirements and regularities of quality assurance and animal welfare. The Company maintains longterm
relationships with research institutes, universities and biotech and pharmaceutical companies,
including eight of the ten largest pharmaceutical companies in the world. The company has been
evaluated by a leading global accounting and auditing firm to be one of the leading companies in HCP
assay development.

phone +49 (0)30 6576 2396
email service@biogenes.de
web www.biogenes.de
email Koepenicker Str. 325 D-12555 Berlin Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

HATRIC-based identification of receptors for orphan ligands (small molecules)

HATRIC-LRC (Ligand Receptor Capture) enables now the identification of small molecule targets on the surface of living cells! Even primary cells!
More info >>


White Papers

Digital Transformation of the Cold Chain

Sensitech EMEA

The Life Sciences cold chain is a seamless and interconnected global network of people, equipment, data and processes that helps to ensure the safety and integrity of our medicines and vaccines. Cold chain logistics spending totaled $13 billion in 2017, an investment designed to protect some $283 billion in Life Sciences cold chain products, growing at 19% annually.1 Sensitech Inc., a part of UTC Climate, Controls & Security, a unit of United Technology Corp., has played an essential part in the Life Sciences cold chain since 1990, providing a comprehensive set of solutions for manufacturers of biologics, prescription pharmaceuticals, clinical trial materials, and over-the-counter drugs. These solutions help to ensure product quality, patient safety, and regulatory compliance while helping to prevent theft and optimizing cold chain performance.
More info >>

Industry Events

3rd PDA Europe Annual Meeting

26-27 June 2018, Berlin Marriott Hotel

The ongoing theme of the European Annual Meeting is Global Healthcare of the Present & the Future, as it intends to continue spanning a bridge between current demands within the global healthcare industry, the amounting advanced technological and analytical opportunities and the promising prospects personalized medicine and medicinal products bring.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement